Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: Contribution of weighting the composite endpoint

European Heart Journal

Volumn 34, Issue 12, 2013, Pages 903-908

  Bakal, Jeffrey A ^a   Westerhout, Cynthia M ^a   Cantor, Warren J ^b   Fernández Avilés, Francisco ^c   Welsh, Robert C ^a   Fitchett, David ^d   Goodman, Shaun G ^d   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angioplasty; Fibrinolysis; Myocardial infarction; Trials

Indexed keywords

ALTEPLASE; TENECTEPLASE;

ARTICLE; DISEASE SEVERITY; EVENT FREE SURVIVAL; FIBRINOLYSIS; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIER ESTIMATE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84875616689     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs438     Document Type: Article

References (26)

1. Bueno H, Armstrong PW, Buxton MJ, Danchin N, Lubsen J, Roland E, Verheugt FW, Zalewski A, Jackson N, Komajda M, Steg PG. Cardiovascular Round Table Clinical Trials ThinkTank participants. The future of clinical trials in secondary prevention after acute coronary syndromes. Eur Heart J 2011; 32:1583-1589.
2. Moyé LA. Multiple Analyses in Clinical Trials: Fundamentals for Investigators. New York, NY: Springer; 2003.
3. Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, Walter SD, Guyatt GH. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007;60:651-657; Discussion 658-662.
4. Armstrong PW, Westerhout CM, Van de Werf F, Califf RM, Welsh RC, Wilcox RG, Bakal JA. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J 2011;161:848-854.
5. Bakal JA, Westerhout CM, Armstrong PW. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. Stat Methods Med Res; Advance Access published Jan 24, 2012, doi: 10.1177/ 0962280211436004.
6. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, Morrison LJ, Langer A, Dzavik V, Mehta SR, Lazzam C, Schwartz B, Casanova A, Goodman SG, TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360:2705-2718.
7. Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006; 27:1530-1538.
8. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, Vazquez N, Blanco J, Alonso-Briales J, Lopez-Mesa J, Fernandez-Vazquez F, Calvo I, Martinez-Elbal L, San Roman JA, Ramos B, GRACIA (Grupo de Analisis de la Cardiopatia Isquemica Aguda) Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364:1045-1053.
9. Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010;55:102-110.
10. Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, Maloney J, McKibbin T, Quinn B, Beanlands RS, Glover C, Marquis JF, O'Brien ER, Williams WL, Higginson LA. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417-424.
11. Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, Winter H, Nickenig G, Bohm M, SIAM III Study Group. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003;42:634-641.
12. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, Dimopoulos K, Manari A, Gaspardone A, Ochala A, Zmudka K, Bolognese L, Steg PG, Flather M, CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008;371:559-568.
13. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, Schunemann HJ, Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ, Guyatt GH. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786.
14. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289:2554-2559.
15. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, Fernandez-Aviles F, Sanchez PL, Dimopoulos K, Scheller B, Armstrong PW, Di Mario C. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010;31:2156-2169.
16. Huque MF, Alosh M, Bhore R. Addressing multiplicity issues of a composite endpoint and its components in clinical trials. J Biopharm Stat 2011;21:610-634.
17. Anstrom KJ, Eisenstein EL. From batting average to wins above replacement to composite end points-refining clinical research using baseball statistical methods. Am Heart J 2011;161:805-806.
18. Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F, STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010;160:30.e1-35.e1.
19. Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM, TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/ non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16.e1-22.e1.
20. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012;33:176-182.
21. Brown MM, Brown GC, Sharma S. Evidence-based to Value-based Medicine. Chicago, IL: American Medical Association Press; 2005.
22. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001;104:1229-1235.
23. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 2009;53:13-20.
24. French JK, Armstrong PW, Cohen E, Kleiman NS, O'Connor CM, Hellkamp AS, Stebbins A, Holmes DR, Hochman JS, Granger CB, Mahaffey KW. Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from 'Assessment of Pexelizumab in Acute Myocardial Infarction'. Am Heart J 2011;162:89-97.
25. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538.
26. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008;51:701-707.